Part II: Interactive case: Drug‐induced endocrine disorders

Abstract

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACYVolume 6, Issue 6 p. 663-668 PSAP IN JACCP Part II: Interactive case: Drug-induced endocrine disorders Amy C. Donihi Pharm.D., FCCP, Amy C. Donihi Pharm.D., FCCP orcid.org/0000-0002-5105-9323 Search for more papers by this author Amy C. Donihi Pharm.D., FCCP, Amy C. Donihi Pharm.D., FCCP orcid.org/0000-0002-5105-9323 Search for more papers by this author First published: 07 June 2023 https://doi.org/10.1002/jac5.1813Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES Aberer F, Hochfellner DA, Sourij H, Mader JK. A practical guide for the management of steroid induced hyperglycaemia in the hospital. J Clin Med. 2021; 10: 2154. Bansal V, El Asmar N, Selman WR, et al. Pitfalls in the diagnosis and management of Cushing's syndrome. Neurosurg Focus. 2015; 38: E4. Barrett B, Bauer AJ. The effects of amiodarone on thyroid function in pediatric and adolescent patients. Curr Opin Pediatr. 2021; 33: 436– 41. Barroso-Sousa R, Barry W, Garrido-Castro A, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens. Jama. 2018; 4: 173– 82. Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M. European thyroid association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction. Eur Thyroid J. 2018; 7: 55– 66. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005; 118: 706– 14. Bhattacharya S, Goyal A, Kaur P, Singh R, Kalra S. Anticancer drug-induced thyroid dysfunction. Eur Endocrinol. 2020; 16: 32– 9. Brancatella A, Viola N, Brogioni S, Montanelli L, Sardella C, Vitti P, et al. Graves' disease induced by immune checkpoint inhibitors: a case report and review of the literature. Eur Thyroid J. 2019; 8: 192– 5. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017; 69: 1521– 37. Burch HB. Drug effects on the thyroid. N Engl J Med. 2019; 381: 749– 61. Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020; 26(suppl 1): 1– 46. Cappellani D, Urbani C, Manetti L, Martino E, Bartalena L, Bogazzi F. Effect of high-dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone-induced thyrotoxicosis: an exploratory study. J Endocrinol Invest. 2020; 43: 1637– 43. Diamanti-Kandarakis E, Duntas L, Kanakis GA, Kandaraki E, Karavitaki N, Kassi E, et al. Diagnosis of endocrine disease: drug-induced endocrinopathies and diabetes: a combo-endocrinology overview. Eur J Endocrinol. 2019; 181: R73– R105. El Badri SAM, Salawu A, Brown JE. Bone health in men with prostate cancer: review article. Curr Osteoporos Rep. 2019; 17: 527– 37. Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI Jr, Murphy EJ, Goldschlager N. Practical management guide for clinicians who treat patients with amiodarone. Am J Med. 2016; 129: 468– 75. Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-induced hyperglycaemia and diabetes. Drug Saf. 2015; 38: 1153– 68. Fève B, Scheen AJ. When therapeutic drugs lead to diabetes. Diabetologia. 2022; 65: 751– 62. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021; 9: 847– 75. Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022; 17: 58. Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017; 7: 1– 12. Hattersley R, Nana M, Lansdown AJ. Endocrine complications of immunotherapies: a review. Clin Med (Lond). 2021; 21: e212– 22. Higham CE, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, Lorigan P, et al. Society for Endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018; 7: G1– 7. Joint British Diabetes Societies for Inpatient Care Group (JBDS-IP). JBDS 08: Management of Hyperglycaemia and Steroid (Glucocorticoid) Therapy. 2022 https://abcd.care/resource/jbds-08-management-hyperglycaemia-and-steroid-glucocorticoid-therapy Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011; 22: 809– 16. Lee SY, Rhee CM, Leung AM, Braverman LE, Brent GA, Pearce EN. A review: radiographic iodinated contrast media-induced thyroid dysfunction. J Clin Endocrinol Metab. 2015; 100: 376– 83. Leslie WD, Morin SN, Lix LM, Niraula S, McCloskey EV, Johansson H, et al. Performance of FRAX in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study. J Bone Miner Res. 2019; 34: 1428– 35. Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol. 2022; 18: 540– 57. Ma RC, Kong AP, Chan N, et al. Drug-induced endocrine and metabolic disorders. Drug Saf. 2007; 30: 215– 45. Markantes GK, Michalaki MA, Vagenakis GA, Lamari FN, Pitsi E, Eliopoulou M, et al. Plasma beta-glucuronidase activity: a novel tool to distinguish type 1 from type 2 amiodarone-induced thyrotoxicosis? Eur Thyroid J. 2019; 8: 215– 20. Miyashita H, Satoi S, Kuno T, Cruz C, Malamud S, Kim SM. Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis. Breast Cancer Res Treat. 2020; 181: 279– 89. Mortensen SJ, Mohamadi A, Wright CL, Chan JJ, Weaver MJ, von Keudell A, et al. Medications as a risk factor for fragility hip fractures: a systematic review and meta-analysis. Calcif Tissue Int. 2020; 107: 1– 9. National Institutes of Health (NIH). Office of Dietary Supplements. Iodine: Fact Sheet for Health Professionals; 2022 Available at https://ods.od.nih.gov/factsheets/Iodine-HealthProfessional/ Roper SM. Yield of serum dexamethasone measurement for reducing false-positive results of low-dose dexamethasone suppression testing. J Appl Lab Med. 2021; 6: 480– 5. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357: 2028– 39. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021; 39: 4073– 126. Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019; 37: 2916– 46. Suh S, Park MK. Glucocorticoid-induced diabetes mellitus: an important but overlooked problem. Endocrinol Metab (Seoul). 2017; 32: 180– 9. Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. 3rd ed. American Society of Health-System Pharmacists; 2018. van Berkel A, Lenders JW, Timmers HJ. Diagnosis of endocrine disease: biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol. 2014; 170: R109– 19. Wallace MD, Metzger NL. Optimizing the treatment of steroid-induced hyperglycemia. Ann Pharmacother. 2018; 52: 86– 90. Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol. 2021; 28:100355. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97: 1802– 22. Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug des Devel Ther. 2019; 13: 2843– 52. Volume6, Issue6June 2023Pages 663-668 ReferencesRelatedInformation